News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|February 27, 2008

Humira approved for juvenile rheumatoid arthritis

Abbott's Humira (adalimumab) had been approved by the food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis...

Abbott's Humira (adalimumab) has been approved by the Food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis.

JVA joins other indications including chronic plaque psoriasis, rheumatoid arthritis in adults, and Crohn's disease.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Meta-analysis finds vegetarian and vegan diets can support healthy growth in children | Image Credit: © vaaseenaa - stock.adobe.com.

Meta-analysis finds vegetarian and vegan diets can support healthy growth in children

ByMorgan Ebert, Managing Editor

December 13th 2025

Edward Hook, MD, reacts to the FDA approval of zoliflodacin for uncomplicated urogenital gonorrhea

Edward Hook, MD, reacts to the FDA approval of zoliflodacin for uncomplicated urogenital gonorrhea

ByEdward Hook, MD

December 12th 2025

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

ByMorgan Ebert, Managing Editor

December 12th 2025

The benefits of gepotidacin for urogenital gonorrhea with Angela Hasler, APRN, CPNP-PC

The benefits of gepotidacin for urogenital gonorrhea with Angela Hasler, APRN, CPNP-PC

By Angela Hasler, APRN, CPNP-PC

December 12th 2025

FDA approves powder formulation of trofinetide for Rett syndrome

FDA approves powder formulation of trofinetide for Rett syndrome

ByMorgan Ebert, Managing Editor,Joshua Fitch, Senior Editor

December 12th 2025

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

Meta-analysis finds vegetarian and vegan diets can support healthy growth in children

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

FDA approves gepotidacin as oral treatment for urogenital gonorrhea

Reports: FDA launching safety review of nirsevimab and clesrovimab for RSV

FDA approves powder formulation of trofinetide for Rett syndrome

© 2025 MJH Life Sciences^®

All rights reserved.